← Leaderboards
Yong Jiang
East Tennessee State University
$1,017,647
Attributed
$1,017,647
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $355K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,017,647 · 1
By mechanism
R01$1,017,647 · 1
Top collaborators
No co-investigators on record.
Most similar at East Tennessee State University
Same institution · by research overlap
- Joel J Hillhouse$2,898,031
- Tammy Regena Ozment$1,502,900
- Zhi Q. Yao$6,116,789
- Robert V Schoborg$2,447,407
- Eric Beaumont$3,838,145
Others in their field
Other Rising Stars on “Adjuvant Chemotherapy”
- Kathryn Marie Jones · Baylor College Of Medicine$3,103,804
- Amy Fowler · University Of Wisconsin-Madison$3,008,001
- Alice Chia- Chi Wei · Sloan-Kettering Inst Can Research$2,617,533
- Nadine Norton · Mayo Clinic Jacksonville$2,431,858
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$2,101,095
- Nduka Mgbechinyere Amankulor · University Of Pennsylvania$2,082,285
Research focus
Adjuvant ChemotherapyEngineered ExosomesApoptosisBiochemicalAttenuatedBreast Cancer CellBreast Cancer PatientBax ProteinCell DeathCell Death InhibitionBiological ModelsCellsCell SurfaceCell SurvivalCessation Of LifeChemoresistanceBreast Cancer TreatmentChemotherapyChemotherapy-Oncologic ProcedureChronicCrispr/Cas TechnologyData SetCell ModelExhibits
Grant awards (3)
Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence$336,458
R01 · FY2025 · CA · contact PI
Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence$326,143
R01 · FY2024 · CA · contact PI
Enhancing chemotherapeutic efficacy in triple-negative breast cancer via DSTYK silence$355,046
R01 · FY2023 · CA · contact PI